Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about Cellular senescence / SASP signaling: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
| Target | Relation | Type | Str |
|---|---|---|---|
| No outgoing edges | |||
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Senescence-Activated NAD+ Depletion Rescue | 0.755 | neurodegeneration | Senolytic therapy for age-related neurod |
| Senescence-Associated Myelin Lipid Remodeling | 0.732 | neurodegeneration | Senolytic therapy for age-related neurod |
| Senescence-Induced Lipid Peroxidation Spreading | 0.730 | neurodegeneration | Senolytic therapy for age-related neurod |
| Apoptosis-Senescence Decision Point Intervention | 0.649 | - | Senescent cell clearance as neurodegener |
| Senescence-Tau Decoupling Therapy | 0.585 | neurodegeneration | Gene expression changes in aging mouse b |
| Timed Senolytic Therapy Eliminates p16^Ink4a/p21^Cip1-Senesc | 0.564 | neuroinflammation | What molecular mechanisms drive the tran |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-01 | 8 hypotheses Top: 0.782
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| dilncRNA-mediated molecular crowding and phase separation | exploratory | 0.900 | 0.00 | cultured cells | proposed | N/A | |
| Mechanism: Why Does Amyloid Removal Only Slow Decline 27%? | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Microglial Aging and Immune Memory in Neurodegeneration — Training the | validation | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $2,960,000 |
| Normal Aging to Alzheimer's Disease Transition Trigger — Identifying t | validation | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $2,280,000 |
| Peroxisomal Dysfunction Validation in Parkinson's Disease | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,280,000 |
| Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer's Disease | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Sirtuin Dysfunction Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Sirtuin Pathway Dysfunction Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Proposed experiment from debate on Senolytics targeting p16/p21+ senes | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $80,000 |
| Proposed experiment from debate on Microglia activate astrocytes via I | falsification | Neuroinflammation | 0.400 | 0.50 | cell_line | completed | $80,000 |
| Iron Dyshomeostasis in MSA Pathogenesis Experiment | validation | Neurodegeneration | 0.400 | 0.50 | human | proposed | $2,280,000 |
| Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $7,100,000 |
| Biomechanical Impact Profiles and Chronic Traumatic Encephalopathy Phe | clinical | Neurodegeneration | 0.400 | 0.50 | in_silico | proposed | $180,000 |
| Ferroptosis Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Peroxisome Dysfunction Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Regulated Necrosis Validation Study in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Traumatic Brain Injury and Alzheimer's Disease Relationship | validation | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $3,000,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Klebsiella pneumoniae Induces Ferroptosis and Lactation Dysfunction in Bovine Ma [PMID:40937759] | Mao P, Wang Z, Duan J, Dong P, Yuan C, L | J Agric Food Chem | 2025 | 1 |
| Targeting ferroptosis: novel therapeutic approaches and intervention strategies [PMID:41425591] | Luo Y, Long M, Wu X, Zeng L | Front Immunol | 2025 | 1 |
| Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and De [PMID:38580317] | Velma GR, Krider IS, Alves ETM, Courey J | J Med Chem | 2024 | 1 |
| Copy number deletion of PLA2G4A affects the susceptibility and clinical phenotyp [PMID:38816399] | Gao Z, Guo X, Sun Z, Wu S, Wang Q, Huang | Schizophrenia (Heidelb) | 2024 | 1 |
| Trimetazidine attenuates Ischemia/Reperfusion-Induced myocardial ferroptosis by [PMID:39134283] | Tan M, Yin Y, Chen W, Zhang J, Jin Y, Zh | Biochem Pharmacol | 2024 | 1 |
| NAD(+) metabolism, stemness, the immune response, and cancer. [PMID:33384409] | Navas LE, Carnero A | Signal Transduct Target Ther | 2021 | 1 |
| NAD metabolism fuels human and mouse intestinal inflammation. [PMID:28877980] | Gerner RR, Klepsch V, Macheiner S, Arnha | Gut | 2018 | 1 |
| NAD+ and sirtuins in aging and disease. [PMID:24786309] | Imai S, Guarente L | Trends Cell Biol | 2014 | 1 |
| Lipoprotein-associated and secreted phospholipases A₂ in cardiovascular disease: [PMID:21098459] | Mallat Z, Lambeau G, Tedgui A | Circulation | 2010 | 1 |
| Phospholipase A2 regulation of bovine endometrial (BEND) cell prostaglandin prod [PMID:18811942] | Godkin JD, Roberts MP, Elgayyar M, Guan | Reprod Biol Endocrinol | 2008 | 1 |
| Discovery of a glycosylated colchicine derivative as a neuroprotective agent for [PMID:41455281] | ["Jash M", "Gupta S", "Garg S", "Khan J" | European journal of medicinal | 2026 | 0 |
| The NADPH oxidase inhibitor Vas2870 prevents myocyte ferroptosis and improves ca [PMID:41671579] | Wang J, Li CM, Yang B, Tantai RN, Guo HX | British journal of pharmacolog | 2026 | 0 |
| Arachidonic acid analog AACOCF3 suppresses cPLA2-negative NSCLC cell proliferati [PMID:41544858] | Wang H, Wen Z, Jia Y, Tong X, Wang W et | Biochem Pharmacol | 2026 | 0 |
| Uncovering the signatures of aging and senescence in the human dorsolateral pref [PMID:41576945] | Sloan NX, Mares J, Daly AC, Grier S, Haq | Cell Genom | 2026 | 0 |
| The Diagnostic Trap in Radiation-Induced Mesothelioma: Kinetic-Morphological Dec [PMID:41595142] | Fujita N, Fujita K, Osumi H, Takefuji Y | Cancers | 2026 | 0 |
| The prognostic impact of CDKN2A/B hemizygous deletions in meningioma. [PMID:41671098] | Ippen FM, Hielscher T, Patel A, Friedel | Neuro Oncol | 2026 | 0 |
| Cdkn2a/p16Ink4a loss impairs Spatial memory independently of Alzheimer's-associa [PMID:41741874] | Stephan P, Plassard D, Keyes WM, Hérault | Cell Mol Life Sci | 2026 | 0 |
| Senolytic therapy ameliorates high-fat diet-induced hippocampal senescence and c [PMID:41895394] | Xia X, Yi F, Zhang R, Wu R, Zhang X et a | Exp Neurol | 2026 | 0 |
| From association to mechanism: Prenatal PFAS Co-exposures induces fetal neural t [PMID:41485332] | Chen Y, Cheng Q, Yang C, Li S, Lin H, Li | Journal of hazardous materials | 2026 | 0 |
| Silencing myeloid cell leukemia-1 improves apoptotic and ferroptotic responses i [PMID:41540498] | Fang F, Xu Q, Shen S, Wang S, Bao C | European journal of medical re | 2026 | 0 |
Multi-agent debates referencing this entity
closed · Rounds: 4 · Score: 0.40 · 2026-04-27
closed · Rounds: 4 · Score: 0.89 · 2026-04-06
Hypotheses and analyses mentioning Cellular senescence / SASP signaling in their description or question text